Clinical Trials Logo

Chronic Disease clinical trials

View clinical trials related to Chronic Disease.

Filter by:

NCT ID: NCT02182869 Terminated - Clinical trials for Pulmonary Disease, Chronic Obstructive

Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)

Start date: April 2001
Phase: Phase 2
Study type: Interventional

Study to evaluate the safety of combivent delivered in two different formulations (hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC)) from a metered dose inhaler (MDI), using a cumulative dose response model in patients with COPD.

NCT ID: NCT02182856 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD

Start date: February 1998
Phase: Phase 4
Study type: Interventional

Study to compare the effects of nebulised salbutamol or ipratropium alone in patients with COPD with those of combined salbutamol and ipratropium nebuliser solution on arterial oxygen saturation (SaO2) and to characterise patients with COPD (chronic obstructive pulmonary disease) at risk of significant arterial oxygen desaturation following nebulised salbutamol.

NCT ID: NCT02182674 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: October 2000
Phase: Phase 2
Study type: Interventional

Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA) inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to two puffs of the marketed chlorofluorocarbon (CFC) containing product, Combivent (CFC) inhalation aerosol (18 mcg ipratropium bromide/103 mcg albuterol sulfate / per puff). The dose response profile, safety and pharmacokinetics of Combivent HFA formulation are to be characterized.

NCT ID: NCT02182635 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: August 1998
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate the long-term safety of Ba253BINEB. Secondarily the long-term efficacy of Ba253BINEB is also investigated.

NCT ID: NCT02182583 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: October 1998
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate the efficacy and safety of Ba253BINEB during the continuous 4 weeks administration to the patients with COPD using Ba253MDI (Tersigan® aerosol) as the comparator drug.

NCT ID: NCT02177344 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease

Start date: August 1998
Phase: Phase 3
Study type: Interventional

The objective of this study is to confirm that chronic dosing of 20 mcg and 40 mcg of ipratropium bromide, administered via the RESPIMAT device, demonstrates clinical comparability and similar safety profiles to the 36 mcg dose of ATROVENT® Inhalation Aerosol (containing chlorinated fluorocarbons (CFC)) in patients with chronic obstructive pulmonary disease (COPD). The efficacy and safety profiles of the two doses administered via the RESPIMAT device will also be compared to their respective placebo groups

NCT ID: NCT02177318 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease

COPD
Start date: April 2005
Phase: N/A
Study type: Observational

To collect post-marketing safety and effectiveness information on the use of Tiotropium Inhalation Capsules (18 μg) in patients with chronic obstructive pulmonary disease in daily clinical settings

NCT ID: NCT02177253 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

Start date: October 2002
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to compare the long-term (12-week) bronchodilator efficacy and safety of ipratropium bromide / salbutamol combination administered by the Respimat® 40 mcg / 200 mcg (one inhalation q.i.d.) to COMBIVENT Inhalation Aerosol (two inhalations q.i.d.), ipratropium bromide Respimat® (one inhalation q.i.d.) and Placebo formulations of each in patients with Chronic Obstructive Pulmonary Disease (COPD). An additional objective was to show the superiority of Combivent Respimat as compared to ipratropium bromide (40 mcg) Respimat. Steady state pharmacokinetics over one dosing interval following four weeks of therapy were also characterized.

NCT ID: NCT02176564 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease

Start date: June 1999
Phase: N/A
Study type: Observational

A pharmaco-epidemiological, observational study that aimed at assessing in a prospective manner the evolution of Quality of Life (QOL) in chronic obstructive pulmonary disease (COPD) patients treated with inhaled bronchodilators

NCT ID: NCT02176200 Terminated - Clinical trials for Pulmonary Disease, Chronic Obstructive

Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: April 2003
Phase: Phase 3
Study type: Interventional

Study to compare the lung and oropharyngeal deposition of Berodual® (fenoterol hydrobromide 50μg + ipratropium bromide 20μg /1x puff) delivered via the Respimat® inhaler and the same dose of Berodual® delivered via an hydrofluoroalkane (HFA) - metered dose inhaler (2 x puffs ) in COPD patients at different inspiratory flow rates.